DOI QR코드

DOI QR Code

Cisplatin Combined with Metformin Inhibits Migration and Invasion of Human Nasopharyngeal Carcinoma Cells by Regulating E-cadherin and MMP-9

  • Sun, Xiao-Jin ;
  • Zhang, Pei ;
  • Li, Hai-Hui ;
  • Jiang, Zhi-Wen ;
  • Jiang, Chen-Chen ;
  • Liu, Hao
  • Published : 2014.05.15

Abstract

Metformin has been shown to be useful in reducing insulin resistance by restoring sensitivity. Recent evidence suggests that metformin might also possess anti-tumour activity. This study aimed to investigate the effects of cisplatin combined with metformin on the proliferation, invasion and migration of HNE1/DDP human nasopharyngeal carcinoma (NPC) cells, and to provide a new target for treating metastasis. The MTT assay was used to assess viability of HNE1/DDP cells after exposure to different concentrations of 2, 5-diaminopyrimidine-4, 6-diol (DDP; 2, 4, 8, 16, and $32{\mu}mol{\cdot}L^{-1}$), metformin (5, 10, 15, 20, and $25{\mu}mol{\cdot}L^{-1}$), and $4{\mu}mol{\cdot}L^{-1}$ of DDP combined with metformin. Wound healing and transwell migration assays were performed to assess cell migration and invasion, and expression of E-cadherin and MMP-9 was detected using Western blotting. MTT assay results showed that DDP could inhibit the proliferation of HNE1/DDP cells in a time- and concentration-dependent manner, with an IC50 of $32.0{\mu}mol{\cdot}L^{-1}$ at 24 h (P < 0.05), whereas low concentrations of DDP had almost no inhibitory effects on cell invasion and migration. DDP combined with metformin significantly inhibited cell invasion and migration. In addition, genes related to migration and invasion, such as those of E-cadherin and MMP-9, showed differential expression in the NPC cell line HNE1/DDP. In the present study, with an increasing concentration of metformin, the expression of MMP-9 was downregulated whereas that of E-cadherin was significantly upregulated. Taken together, our results show that cisplatin combined with metformin has effects on proliferation, invasion, and migration of human NPC cells.

Keywords

Metformin;cisplatin;NPC;invasion;metastasis

References

  1. Zakikhani M, Dowling R, Chen J et al (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 66, 10269-73. https://doi.org/10.1158/0008-5472.CAN-06-1500
  2. Witters LA (2001). The blooming of the French lilac. J Clin Invest, 108, 1105-7. https://doi.org/10.1172/JCI14178
  3. Wurth R, Pattarozzi A, Gatti M et al (2013). Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle, 12, 145-56. https://doi.org/10.4161/cc.23050
  4. Wu B , Li S, Sheng L et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep, 28, 903-8.
  5. Hwang YP, Jeong HG (2010). Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol, 160, 1195-211. https://doi.org/10.1111/j.1476-5381.2010.00762.x
  6. Fan FT, Shen CS, Tao L et al (2013). PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation. Asian Pac J Cancer Prev, 14, 5533-7. https://doi.org/10.7314/APJCP.2013.14.9.5533
  7. Huang CD , Tang MZ. (2009). Progress of treating nasopharyngeal carcinoma by Chinese pharmacy and radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi, 33, 1575-8.
  8. Hsieh MC, Lee TC, Cheng SM et al (2012). The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res, 2012, 413782.
  9. Jiralerspong S, Palla SL, Giordano SH et al (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 2, 3297-302.
  10. Kato K , Gong J, Iwama H et al (2012). The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther, 11, 549-60. https://doi.org/10.1158/1535-7163.MCT-11-0594
  11. Rattan R, Giri S, Hartmann LC et al (2011). Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Mech , 15, 166-78. https://doi.org/10.1111/j.1582-4934.2009.00954.x
  12. Rattan R, Graham RP, Maguire JL et al (2011). Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 13, 483-91. https://doi.org/10.1593/neo.11148
  13. Tan BK, Adya R et al (2011). Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab, 96, 808-16. https://doi.org/10.1210/jc.2010-1803
  14. Anisimov VN , Berstein LM , Egormin PA et al (2005). Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol, 40, 685-93. https://doi.org/10.1016/j.exger.2005.07.007
  15. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF et al (2010). Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther, 9, 1092-9. https://doi.org/10.1158/1535-7163.MCT-09-1186
  16. Ben Sahra I, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86. https://doi.org/10.1038/sj.onc.1211024
  17. Chen J, Dassarath M, Yin Z et al (2011). Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management. Radiat Oncol, 6, 128. https://doi.org/10.1186/1748-717X-6-128
  18. Decensi A, Puntoni M, Goodwin P et al. (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res, 3, 1451-61. https://doi.org/10.1158/1940-6207.CAPR-10-0157
  19. Fedorcsak P, Dale PO, Storeng R et al. (2003). The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecol Endocrinol, 17, 207-14. https://doi.org/10.1080/713603249

Cited by

  1. Mangiferin Induces Apoptosis by Regulating Bcl-2 and Bax Expression in the CNE2 Nasopharyngeal Carcinoma Cell Line vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7065
  2. microRNA-20a enhances the epithelial-to-mesenchymal transition of colorectal cancer cells by modulating matrix metalloproteinases vol.10, pp.2, 2015, https://doi.org/10.3892/etm.2015.2538
  3. Effects of Metformin on Cell Kinetic Parameters of MCF-7 Breast Cancer Cells in Vitro vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2351
  4. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3751-1
  5. Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression vol.76, pp.6, 2015, https://doi.org/10.1007/s00280-015-2902-9
  6. Metformin may protect nondiabetic breast cancer women from metastasis vol.33, pp.4, 2016, https://doi.org/10.1007/s10585-016-9782-1
  7. Gene Polymorphism with Nasopharyngeal Carcinoma vol.19, pp.4, 2015, https://doi.org/10.1089/gtmb.2014.0149